227. オスラー病 Osler disease Clinical trials / Disease details

臨床試験数 : 54 / 薬物数 : 73 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

diseases per page:

Showing 1 to 10 of 54 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-004179-11-IT (EUCTR)	03/09/2021	17/08/2021	Effectiveness of somatostatin analogues for GI bleeding in patients with hereditaryhemorrhagic telan ...	Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagictelangiectasia and sy ...	Hereditary hemorrhagic telangiectasia(HHT), also known as Osler–Weber–Rendu disease(in specific pati ...	Product Name: octreotide a azione pronta 0,1 mg Product Code: [OCTREOTIDE ACETATO] INN or Proposed INN: ...	RADBOUD UNIVERSITY MEDICAL CENTER	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	38	Phase 3	France;Denmark;Netherlands;Germany;United Kingdom;Italy
2	ChiCTR2100043253	2021-02-17	2021-02-09	The study of genotype analysis of HHT patients in china and clinical efficacy study of bevacizumab i ...	The study of genotype analysis of HHT patients in china and clinical efficacy study of bevacizumab i ...	hereditary hemorrhagic telangiectasia	Trial group:Bevacizumab;	Shandong Provincial ENT Hospital	NULL	Recruiting	16	75	Both	Trial group:30;	Phase 4	China
3	EUCTR2018-004179-11-FR (EUCTR)	20/01/2021	26/11/2020	The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber di ...	Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasiaand sy ...	Hereditary hemorrhagic telangiectasia(HHT);Therapeutic area: Diseases [C] - Congenital, Hereditary, ...	Trade Name: Octreotide INN or Proposed INN: OCTREOTIDE	Radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	38	Phase 3	France;Germany;Netherlands
4	NCT04404881 (ClinicalTrials.gov)	November 23, 2020	22/5/2020	Bevacizumab In Hereditary Hemorrhagic Telangiectasia	A Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrh ...	Hereditary Hemorrhagic Telangiectasia	Drug: Bevacizumab	Hanny Al-Samkari, MD	NULL	Recruiting	18 Years	N/A	All	20	Phase 2	United States
5	NCT04646356 (ClinicalTrials.gov)	October 20, 2020	20/10/2020	Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)	Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)	Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed	Drug: Tacrolimus capsule (low-dose)	Unity Health Toronto	United States Department of Defense	Recruiting	18 Years	N/A	All	30	Phase 2	Canada
6	EUCTR2018-004179-11-DE (EUCTR)	12/08/2020	12/03/2020	The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber di ...	Effectiveness of Somatostatin Analogues in Patients with hereditaryhemorrhagic telangiectasia and sy ...	Hereditary hemorrhagic telangiectasia(HHT), also known as Osler–Weber–Rendu disease (in specific pat ...	Other descriptive name: OCTREOTIDE ACETATE	Radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	38	Phase 3	Italy;United Kingdom;Germany;Netherlands;France
7	NCT04113187 (ClinicalTrials.gov)	June 23, 2020	27/9/2019	Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients	Study of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telan ...	Hereditary Hemorrhagic Telangiectasia;Osler Weber Rendu Disease	Drug: Propranolol treatment;Drug: Placebo	University Hospital, Bordeaux	AMRO-HHT-France - Association Maladie de Rendu-Osler	Active, not recruiting	18 Years	N/A	All	15	Phase 3	France
8	NCT03954782 (ClinicalTrials.gov)	June 22, 2020	15/5/2019	Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.	Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. A National, Randomized, M ...	Telangiectasia, Hereditary Hemorrhagic;Rendu Osler Disease	Drug: Nintedanib 150 mg and 100 mg soft capsules;Drug: Oral treatment of placebo soft capsule	Hospices Civils de Lyon	NULL	Recruiting	18 Years	N/A	All	60	Phase 2	France
9	EUCTR2019-003585-40-NL (EUCTR)	17/12/2019	30/09/2019	Tacrolimus for bleeding in hereditary hemorrhagic telangiectasia patients	An uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and th ...	Gastrointestinal bleeding and epistaxis caused by hereditary hemorrhagic telangiectasia. Hereditary ...	Trade Name: Tacrolimus (Advagraf) Product Name: Tacrolimus (Advagraf) Product Code: EMEA/H/C/000712	St. Antonius Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Netherlands
10	EUCTR2019-002593-31-FR (EUCTR)	05/11/2019	05/09/2019	Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseEPICURE	Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseA national, randomized, mul ...	Hereditary Hemorrhagic Telangiectasia MedDRA version: 20.1;Level: LLT;Classification code 10019887;T ...	Trade Name: OFEV Product Name: nintédanib Other descriptive name: NINTEDANIB	Hospices Civils de Lyon	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	France

First Previous1 2 3 4 5 6Next Last